# Long-Term Effects of Chronic Hemiparetic Stroke and Botulinum Neurotoxin on Wrist and Finger Passive Mechanical Properties

Benjamin I Binder-Markey[1,2,3,4,5,6] DPT, PhD, Wendy M Murray[3,4,5,6,7], PhD, *Julius P.A. Dewald[3,4,5] PT, PhD

[1]Department of Physical Therapy and Rehabilitation Sciences, Drexel University, Philadelphia, PA
[2]School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA
[3]Department of Biomedical Engineering, Northwestern University, Evanston, IL
[4]Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL
[5]Department of Physical Medicine and Rehabilitation Science, Northwestern University, Chicago, IL
[6]Shirley Ryan Ability Lab, Chicago, IL
[7]Research Service, Edward Hines Jr., VA Hospital, Hines, IL

**\*Corresponding Author**
\*Julius PA Dewald, PT, PhD
645 N. Michigan Ave
Suite 1100
Chicago, IL 60611
Phone: (312) 908-6788
j-dewald@northwestern.edu

Word Count: 4469
Figure Count: 4, 1 supplemental
Table Count: 2

**ABSTRACT**

**Background:** Neural impairments that follow hemiparetic stroke may negatively affect passive

muscle properties, further limiting recovery. However, factors such as hypertonia, spasticity, and

botulinum neurotoxin (BoNT), a common clinical intervention, confound our understanding of

muscle properties in chronic stroke.

**Objective:** To determine if muscle passive biomechanical properties are different following

prolonged, stroke-induced, altered muscle activation and disuse.

**Methods:** Torques about the metacarpophalangeal and wrist joints were measured in different

joint postures in both limbs of participants with hemiparetic stroke. First, we evaluated 27

participants with no history of BoNT; hand impairments ranged from mild to severe.

Subsequently, seven participants with a history of BoNT injections were evaluated. To mitigate

muscle hypertonia, torques were quantified after an extensive stretching protocol and under

conditions that encouraged participants to sleep. EMGs were monitored throughout data

collection.

**Results:** Among participants who never received BoNT, no significant differences in passive

torques between limbs were observed. Among participants who previously received BoNT

injections, passive flexion torques about their paretic wrist and finger joints were larger than

their nonparetic limb (average interlimb differences = +42.0±7.6SEM Ncm, +26.9±3.9SEM

Ncm, respectively), and the range of motion for passive finger extension was significantly

smaller (average interlimb difference = -36.3°±4.5°SEM; degrees).

**Conclusion:** Our results suggest that neural impairments that follow chronic, hemiparetic stroke

do not lead to passive mechanical changes within the wrist and finger muscles. Rather, consistent

with animal studies, the data points to potential adverse effects of BoNT on passive muscle

properties post-stroke, which warrant further consideration.

*INTRODUCTION*

Following a hemiparetic stroke, induced damage to corticofugal motor (i.e., corticospinal and

corticobulbar) pathways result in an increased reliance on indirect contralesional

corticoreticulospinal pathways.[1-5] This shift alters neural input to spinal motor neurons resulting

in motor impairments such as weakness,[6-8] loss of independent joint control,[9-13] and motor

neuron hyperactivity manifesting as hypertonia and spasticity (i.e., hyperactive stretch

reflexes).[14-18] This altered motor drive and associated limb use, over time, may change muscle

structure and function, further amplifying the brain injury induced motor impairments.

Additionally, botulinum neurotoxin (BoNT) chemical denervation, widely used to treat muscle

hypertonia and spasticity,[19-21] may also alter muscle.[22-29] One particularly detrimental sequelae of

these muscle adaptations are that muscles can become increasingly stiff, making movement

progressively more difficult.

There is not a clear consensus regarding how prolonged exposure to altered neural inputs

following a stroke affect muscle structure and its associated passive mechanical properties.

Previous studies quantifying muscle adaptions following a stroke have demonstrated decreased

fascicle lengths,[30-32] often accompanied by increased joint torques and stiffness[7,30,31,33-37]. Such

data has been interpreted as evidence of muscle contractures and mechanical property

adaptations. However, conflicting evidence also suggests that passive mechanical properties are

not different between the paretic and non-paretic limbs of stroke survivors.[33,38]

Abnormal muscle hypertonia and spasticity increase the chance of muscle activity, even in

conditions intended to be "passive" or "relaxed". Thus, conflicting results could be a

consequence of differences in how effectively abnormal muscle hyperactivity was controlled

among different studies. For example, some studies utilized continuous motion to collect passive

torques.[7,35,36] However, even low constant velocities elicit hyperactive stretch reflexes that

substantially increased paretic finger torques.[8] In other studies, EMGs were not recorded to

confirm muscles were passive during data collection.[30,38] Additionally, some methods involved

dynamic analytical models to decompose active torques and estimate passive torques from

muscle activity and EMGs estimated rather than directly measuring passive torques.[7,34,36] Finally,

while pre-stretching attenuates hyperactive motoneurons and the stretch reflex,[39] few studies

discuss whether stretching prior to data collection was utilized.[7,30,35,36,38] Such methodological

differences among previous studies obfuscate our understanding of muscle passive properties

following chronic stroke.

An additional confounding factor, neither discussed nor reported in the context of the

inclusion/exclusion criteria in previous studies, is the potential long term effects of BoNT. BoNT

chemical denervation is included in neurological clinical practice guidelines for treatment of

adult spasticity[19]; it is a common treatment for muscle hypertonia and spasticity[19-21] within the

~45% of stroke survivors who have spasticity.[40,41] Presumably, the short term, BoNT-induced

reduction of muscle tone[20] improves function by increasing range of motion (ROM) and

reducing overall hypertonicity. Yet, evidence of these beneficial effects is limited and based

largely on acute, subjective clinical assessments of muscle tone and ROM without demonstrating

improvements in either active function or quality of life.[21,42,43] In contrast, both acute and chronic

structural changes in rodent muscles have been observed following BoNT injections, including

increased intramuscular connective tissue and passive mechanical stiffness.[22-26,28,29] If BoNT

administration imposes the same effects within human muscle, it is critical to understand both

how these structural changes are distinct from stroke-induced alterations and the extent to which

the induced structural changes may effect optimal functional recovery.

The overall objective of this study is to determine the extent to which muscle passive

biomechanical properties in the paretic limb differ from non-paretic limb given prolonged,

stroke-induced, altered muscle activation and use; as well as potential long-terms effects of

BoNT administration. To do so, we compared the passive torques collected about the paretic and

non-paretic wrist and finger joints of individuals with chronic hemiparetic stroke, while

controlling for muscle hyperactivity and accounting for BoNT use. We chose to study wrist and

finger muscles because they are affected by the longest lasting and most severe motor

impairments following a stroke[44-47] and are a frequent site of BoNT treatment. To evaluate the

long term effects of stroke-induced neural impairments, we recruited individuals with mild to

severe hand impairments with no history of BoNT injections. To understand long-term effects of

BoNT, and resulting chemical denervation, we recruited additional chronic stroke participants

with a history of BoNT treatment.  Based on the prevailing findings of previous literature and the

common clinical presentation of stiff, flexed wrists and fingers in the paretic limb following

stroke, our primary hypothesis is that passive torques in the paretic hand are greater than the non-

paretic hand.

**MATERIALS AND METHODS**

**Participants**

The Clinical Neuroscience Research Registry from Northwestern University and the Shirley

Ryan Ability Lab was used to pre-screen individuals with chronic hemiparetic stroke based on

set inclusion/exclusion criteria (Table 1). 105 individuals whose registry-based, prior clinical

assessments of upper limb impairment fit the screening criteria were contacted; 68 individuals

responded. In this screening (no-BoNT), previous history of BoNT injections in their arms was

an exclusion criteria. After registry-based stratification into different impairment levels (mild,

moderate, and severe) and further verification that inclusion/exclusion criteria were met 39

individuals were invited; 28 agreed to participate and were enrolled. Once enrollment of the no-

BoNT participants was complete, we contacted 23 individuals with a previous history of BoNT

injections. Eleven individuals met our enrollment criteria for the BoNT-injected group; 10 were

enrolled. Each of these participants received BoNT injections within their forearm flexor

compartment. A single enrollee in the BoNT group was subsequently excluded due to also

having received BoNT injections in the forearm extensor compartment. The 9 remaining

individuals were at least one year post-BoNT injection. After testing was completed on all

enrolled participants, the data from three additional enrollees (2, BoNT-injected; 1, no-BoNT)

were excluded from the analysis due to the inability to relax during testing, as determined by

EMG activity.

Enrolled study participants were ultimately stratified by hand impairment using the Chedoke

McMaster Stroke Assessment Hand Score (CMSA-HS)[48], administered at the time of testing by a

licensed physical therapist (Table 2). Severe impairments were defined as CMSA-HS scores of

1-3 (n=9 no-BoNT; n=7 BoNT-injected), moderate impairments as 4-5 (n=9 no-BoNT), and mild

impairments as 6-7 (n=9 no-BoNT). Clinical scores (both CMSA-HS and Modified Ashworth

Scale (MAS)) for all 7 participants with a history BoNT injections indicated severe impairment;

scores were not significantly different (p=0.196, p=0.158, respectively) from those with severe

impairments and no history of BoNT (Table 2). Demographic data were gathered from all

participants prior to data collection.

Initial enrollment targets (n = 9 per group: no-BoNT mild, moderate, severe, and BoNT-

injected) were defined to surpass the conditions needed to detect a large effect size (Cohen's d =

1.1), based on a priori power analyses of a one-tailed, within-subject t-test for the hypothesis that

passive torques in the paretic limb are greater than the non-paretic limb. Due to the lack of

appropriate passive torque data, we powered the study based on the detectable interlimb

differences in the passive range of motion limits for MCP extension. Specifically, Cohen's d was

calculated from the angular resolution of the device used to measure MCP torque (15°) and

intersubject variability at the limit of MCP extension in nonimpaired participants.[49] The analysis

indicated that with our large, standardized effect size, a power of 0.8 would be achieved with α =

0.05 and 7 participants.[50] With the same assumptions, an a priori power analysis for one-way

(between groups) ANOVA indicated that a total of 16 participants were needed.[50] The total

participant numbers for the results presented here (n = 34) are more than double the total

specified via the a priori ANOVA analysis. Participant numbers within each of the 4 distinct

groups either meet or exceed the number specified via the a priori analysis for a single t-test (n =

7).

The study protocol was developed in compliance with the Declaration of Helsinki and

approved by the Institutional Review Board (IRB) of Northwestern University (IRB Study:

STU00203691). Participants gave informed consent prior to participation and all patients signed

a Patient Consent-to-Disclose form prior to any images being taken.

*Experimental Set-up*

A custom built device[51] was used to collect torques produced about the wrist and fingers. The

device allows the experimenter to position the wrist and metacarpophalangeal (MCP) joints

separately, in discrete 15° increments, while simultaneously collecting torques about each joint.

Participants were seated in an upright position with their hand secured in the device.  The

participant's arm was positioned comfortably at their side with the forearm parallel to the ground

and palm facing medially. The two distal finger joints were splinted. Muscle activity was

monitored throughout each trial using surface electrodes (16-channel Bagnoli EMG System,

Delsys Inc., Boston, MA; 1000 x gain, 20-450 Hz bandpass) placed over 4 muscles; Flexor

Digitorium Superficialis, Flexor Carpi Ulnaris, Extensor Digitorium Communis, and Extensor

Carpi Radialis Longus.

*Muscle Hyperactivity Inhibition Protocol*

Muscle hyperactivity was reduced and quieted during data collection by providing conditions

that encouraged participants to sleep. This relaxed state reduces reticulospinal tract activity

resulting in decreased spinal motoneurons excitability and muscle hyperactivity.[52-54] We

encouraged sleep by creating a dark atmosphere and playing relaxing videos or music. Each

session began with 10-15 minutes of stretching of the shoulder, elbow, wrist, and fingers

muscles. Participants were then positioned into the device. The lights were turned off, the video

or music was turned on, and these conditions remained in effect for the remainder of the

protocol. An additional 10 minutes of 90 second sustained stretches of the wrist and fingers

muscles were performed, accomodating the individual to the device. Decreases in EMG activity

and measured torques were observed at this point (Figure 1). The device's MCP and wrist

restraints were unlocked, allowing the wrist and fingers to move and rest at their equilibrium

postures. Three 15-second baseline trials with no evidence of EMG activity were then collected

to zero the device and define passive EMG baseline.

*Experimental Procedure*

The protocol for each limb was completed on two consecutive days, if possible. Data

collection took four to six hours per limb. Data from the non-paretic hand was collected on the

first day to acclimate the individual to the procedure. Because of the sensitive nature of muscle

hyperactivity in the paretic limb, we felt the benefits of testing that limb after the participant was

fully comfortable with the full protocol and able to maximally relax outweighed any costs

associated with not randomizing for limb across days. Passive torques were collected from a

maximum of 108 combinations of wrist and MCP joint postures, depending on the individual

participant's available ROM. MCP and wrist ROM were determined within the device; we

recorded the largest 15° increment reached for each degree of freedom. The most extreme

postures that could be reached by each participant within the device were determined by the

individual's comfort level or the device's limits.

Torques were collected at static postures. Wrist posture was randomly set in 15° increments

between 60° of flexion and 60° of extension (9 wrist postures). One participant (BoNT-injected)

had limited wrist extension in the paretic limb, and could only be positioned in 6 postures. At

each wrist posture, the MCP joints were positioned in full extension, moved to full flexion, and

then moved back to full extension in static 15° increments. At each static posture, data were

collected for 15 seconds and visually inspected. Trials for which there was clear evidence of

muscle activity and corresponding torque deviations during testing were discarded and repeated.

***Data processing***

Raw torque and EMGs were collected and digitized (CED Micro 1401 MkII, Cambridge

Electronic Design, Cambridge, UK) at a 1 kHz sampling frequency using Spike2 software

(Cambridge Electronic Design, Cambridge, UK). The torque and rectified EMG data were then

digitally filtered using a zero-phase infinite impulse response 4th-order Butterworth low-pass

filter with a 4Hz corner frequency within MATLAB.

The processed baseline trials defined the torque offset and EMG threshold. Torque offset was

defined as the average torque measured during the three baseline trials. EMG threshold, $EMG_t$,

was defined as:

$$EMG_t = \bar{x}_{EMG\_base} + 3 \cdot \sigma_{EMG\_base}$$

where $\bar{x}_{EMG\_base}$ is the average of the three EMG baseline trials and $\sigma_{EMG\_base}$ is the average

EMG standard deviation over the three baseline trials.

For each static trial (i.e., the torque produced in a single combination of wrist and MCP joint

positions), the processed torque and EMG data were divided into 1-second bins, resulting in 15

bins per trial. The average torque and EMG values were first calculated for each of the 15 bins.

For a given 1-second bin in any trial, if the average EMG signal from any muscle

exceeded $EMG_t$ or if the torque deviated $\geq$ 5% from the mode across the entire trial, the bin was

discarded. The average of the remaining bins within each trial were used to create the total

torque versus wrist and MCP posture data set for each subject.

Differences in torques between limbs were calculated by subtracting non-paretic torque from

paretic torque at each posture. Differences in MCP extension passive ROM (ePROM) between

hands were calculated at each wrist posture. When data were missing or discarded, the difference

was only calculated for postures where data was available in both paretic and non-paretic hands.

**_Data Analysis_**

To test our primary hypothesis that passive torques in the paretic hand are greater than the

non-paretic hand within each group (severe BoNT-injected, severe no-BoNT, moderate, and

mild), we compared the differences between the participants' paretic and non-paretic hands for

MCP joint torques and wrist joint torques. Secondarily, we compared torque differences across

groups and evaluated the interlimb differences for ePROM across all wrist postures. A distinct

linear-mixed model (LMM) was implemented in SPSS (v26.0 IBM Corp Armonk, NY) for each

parameter of interest (i.e., 3 models). LMMs allow for within-participant experimental designs

by correcting for repeated measurements within participants while allowing for missing data

points.[55]

When interlimb difference in MCP or wrist torques was the dependent variable, the linear-

mixed model fixed effects included group, MCP position, wrist position, and their interactions.

When interlimb difference in ePROM was the dependent variable, fixed effects included group,

wrist position, and their interaction. An intercept random effect for participant was included in

all models to account for random differences across participants.

Within each of the 4 impairment groups, post-hoc t-tests were used to test if the within-

subject, interlimb torque differences were significantly different from zero. Significance was

calculated using the T.DIST.RT function in Microsoft Excel (2020); inputs were the ratio of the

marginal mean and standard error for each group and the degrees of freedom, all outputs from

the LMM model in SPSS. To determine between group differences, post-hoc pairwise

comparisons among the groups were performed. Significance of the pairwise comparisons were

also calculated using the T.DIST.RT Excel function and outputs from the LMM models. To

maintain $p<0.05$ as threshold of significance globally, the threshold for individual t-tests in the

post-hoc analyses was reduced using the Bonferroni correction for multiple comparisions to

$p=0.005$ ($p=0.05/10$). Across each dependent variable there were 10 post-hoc comparisons: the

within-subject, different from zero comparison for each of the 4 groups, and 6 between group

comparisons. Results are reported as average ± one standard deviation unless otherwise noted.

Finally, to assess whether the differences in observed, mean, within-subject interlimb differences

met our a priori assumptions, we calculated the Cohen's d effect size achieved for each

combination of wrist and MCP joint posture from the experimental data.

***Data availability***

The data sets used within this analysis are available by request from the authors.
264
**RESULTS**

***Passive Torque about the Wrist and MCP joints***

Interlimb differences in MCP joint torques were small and were not significantly different for the

mild (p= 0.188), moderate (p=0.046), or severe (p=0.017) impairment groups without a history

of BoNT injections (cf., rows 1-3, Fig. 2a, p<0.005 is the threshold for significance for post-hoc

t-tests). In contrast, the BoNT-injected group had significantly greater MCP joint torques in their

paretic versus non-paretic hands (Fig. 2; p=$5.83 \times 10^{-8}$). The observed effects in interlimb

differences for the the BoNT group were consistent with the large effect sizes (Cohen's d = 1.1)

we powered the study to detect. For example, the average of the achieved standardized effect

size for all postures was 1.24±1.09 (range = 0.10-8.64), with effect sizes generally increasing

with wrist and MCP extension. Effect sizes observed for interlimb MCP torque differences for

the impairment groups without a history of BoNT were smaller, with mean Cohen's d across all

postures of 0.77±1.2, 0.49±0.33, and 0.47±0.63 for the severe, moderate, and mild groups,

respectively. Interlimb differences in MCP torque increased with wrist and MCP extension for

the BoNT group only (Fig 2b). The interlimb difference in MCP torques observed in the BoNT

group were significantly greater than each no-BoNT group (p < $4.47 \times 10^{-4}$ for all, Fig. 2b)

Passive torques at the wrist replicated the findings at the MCP joints. Specifically,

significant differences in passive wrist torques between limbs were only observed in the BoNT

group (p = 4.51 x10$^{-6}$; Fig. 3a). The distinction in standardized effect sizes observed in the BoNT

group compared to the 3 no-BoNT groups was even greater for wrist torques than for MCP

torques. The average, achieved standardized effect size (Cohen's d) for interlimb wrist torque

differences across all postures was 1.65±1.28 (range = 0.35-8.38) for the BoNT group compared

to 0.30±0.35, 0.33±0.25 and 0.32±0.34 for the mild, moderate, and severe no-BoNT groups,

respectively. Between groups, the interlimb difference in wrist torques observed in the BoNT

group was significantly greater than each of the no-BoNT groups (p < 2.10x10$^{-3}$ for all;  Fig. 3b).

***Impact on Passive Range of motion***

In general, the observed effects for passive MCP extension ROM in the three no-BoNT

groups were small, especially when compared to the BoNT group. For the severe and mild no-

BoNT groups, the passive limits of MCP extension were not significantly different between

limbs; with ePROM differences of -3.15°±19.02° (p=0.216) and 2.47°±9.12° (p=0.274) and

standardized effect sizes of 0.24±0.23 and 0.30±0.24 averaged across the 9 wrist postures tested,

respectively. For the moderate no-BoNT group, the limit of passive MCP extension was

12.0°±3.9° less extended in the paretic limb than the non-paretic limb (p = 2.18x10$^{-3}$), a

significant interlimb difference that was on the same order as the measurement resolution for

ePROM in this study (15°). In contrast, for the BoNT-injected group, the interlimb difference in

ePROM across all wrist angles was much larger (-36.3°±4.5°; p=1.94x10$^{-9}$).

***DISCUSSION***

The main objective of this study is to determine the extent to which the prolonged changes in

neural input and muscle use experienced by individuals with a chronic hemiparetic stroke are

associated with differences in muscle passive biomechanical properties between limbs. To this

purpose, we evaluated a cohort of 27 individuals with chronic hemiparetic stroke, with no history

of BoNT injections, spanning mild to severe hand impairments and an additional 7 individuals

who had previously received BoNT injections, all with severe hand impairments. Our primary

hypothesis was that passive torques in the paretic hand are greater than in the non-paretic hand.

Strikingly, in the participants without BoNT, we did not observe significant interlimb passive

torque differences at either the wrist or the MCP joints. Importantly, we powered the study to

detect large effect sizes, and the significant results observed for the BoNT group demonstrate

that we did enroll sufficient participant numbers to detect the large standardized effect sizes we

expected to observe. However, the standardized effect sizes observed in the no-BoNT groups

were much smaller than we anticipated. Overall, the small absolute magnitude of the interlimb

torque differences (c.f. Figs 2b & 3b) paired with the small absolute magnitude of interlimb

ePROM differences observed (c.f. Fig 4) among the no-BoNT groups suggest that the observed

torque differences in the paretic limb are not a critical impediments to passive ROM after a

stroke.

Unlike many previous studies following chronic hemiparetic stroke,[7,30,31,33-37] we did not

observe greater passive torques in the paretic limb among the participants who had never

received BoNT. Most of the previous studies evaluated lower extremity (ankle)[30,31,33,34,37] or

more proximal (elbow)[33,35] joints; we studied distal wrist and finger joints. Following a stroke,

the loss of corticospinal projections has a significantly greater impact on distal wrist and finger

function than more proximal upper extremity joints.[56] By replacing corticospinal drive with the

indirect corticoreticulospinal system there is a significant neuromodulatory effect on spinal

motorneurons due to greater release of monoamines (serotonin and norepinephrine) in the spinal

cord.[57] This increase of monoamines causes motoneuron hyperexcitability and increased

involuntary muscle activation or hypertonia, which especially effects the distal wrist and finger

muscles.[15,57,58] This increased hypertonia and continuous activation may cause greater

impairments of these more distal muscles during movement but it also may serve a protective

effect on the muscle structure preventing significant atrophy and passive mechanical changes.

This is an area that should be further explored and is currently under investigation within our lab.

Another factor contributing to the differences between our study and previous studies is

the great care we took to reduce muscle hyperactivity during data collection. Inconsistencies

between our results and previous studies may underscore the importance of this factor.

Especially at the wrist and fingers, simple instructions to relax are likely insufficient. Many

individuals with chronic stroke are unable to fully relax while awake due to reticulospinal

mediated motoneuron hyperexcitability and muscle hypertonia. Decreasing hypertonia of

muscles may require a significant reduction in corticoreticulospinal tract activity,[52-54] that we

addressed by encouraging participants to sleep during testing. A decrease in muscle activity was

observed during test preparations (Figure 1), activity levels were strictly monitored throughout

data collection. These critical steps should be considered when attempting to quantify passive

muscle mechanics *in vivo* within any future study within a "spastic" population.

This study is also unique because we explicitly stratified participants based on prior

clinical history of BoNT. Clinically, BoNT injections are frequently administered to alleviate

muscle hyperactivity or hypertonia within the wrist and finger muscles. Approximately 45% of

stroke survivors have spasticity[40,41] and BoNT is the preferred treatment for decreasing muscle

hyperactivity and increasing ROM. Each of our participants' final BoNT injection was at least

four years prior to our data collection (Table 2). Within our BoNT-injected group, we observed

interlimb torque differences that were significantly larger than those observed in the no-BoNT

groups. The BoNT-injected group was also the only group where we observed interlimb torque

differences that systematically increased with wrist and MCP extension (Figures 2b & 3b).

Extended postures lengthen the wrist and finger flexor muscles, which are the muscles that were

injected with BoNT. Thus, our results suggest the possibility of a long lasting negative effect of

BoNT: substantially increased passive muscle stiffness.

The increased passive joint torques we observed in the paretic limb in the BoNT group

was also associated with substantial deficits in passive MCP extension relative to the nonparetic

limb (Figure 4). This chronic limitation in ROM contrasts with acute increases in passive ROM,

observed 1-2 months following BoNT injection.[59] Importantly, the deficits in passive ROM we

observed likely underestimate the extent that active ROM would be affected. We would expect

even larger losses in active ROM as active finger extensor strength decreases by as much as

90%[6-8] and therefore would likely be unable to overcome the increased passive torques about the

fingers.

Previous animal studies demonstrate increased collagen content in the muscle following

BoNT injections; these increases were observed within 6 months and lasted the animal's

lifespan.[22,23,26] The underlying mechanism of this increased collagen content is unknown.

Because BoNT chemically denervates a muscle the resulting adaptation may be similar to

traditional muscle denervation. Denervated muscle has been shown to demonstrate increases in

collagen content within a month after denervation[60,61] and a recent study comparing muscle

treated with BoNT and a denervated muscle demonstrated similar patterns of progressive atrophy

and collagen content increases (Richard L. Lieber, personal communication of unpublished data,

2019). If BoNT is going to continue to be the 'go to' treatment for muscle hypertonia, further

studies into the mechanism by which BoNT affects muscle are necessary to enhance our

understanding of its long-term effects and to optimize recovery post stroke.

Because we quantified joint properties, we are unable to discern how mechanisms at the

muscle level, such as atrophy (loss of contractile material), adaptations of muscle extra-cellular

matrix (ECM), tendon compliance, or their combination) contribute to our results. In general, no

study quantifying joint properties can distinguish between effects due to adaptations in muscle

architecture, ECM, or tendon compliance. Future work could incorporate muscle imaging and

tissue analyses to further quantify the impact of potential muscle volume and structural changes.

Another important limitation of this study is that it is a cross-sectional study. While we

report striking differences between interlimb differences in passive joint torques and the range of

motion between the BoNT group and the no-BoNT groups, our data does not establish causality

between the BoNT injections and increased muscle or joint stiffness. Similarly, because this is

not a prospective, longitudinal study we are not reporting observations of adaptations in chronic

stroke muscle over time. Despite these limitations, the within subject control provided by the

non-paretic limb provides a valuable comparison in our retrospective study.

Finally, based on our a priori expectations for interlimb differences, we powered the

study to detect changes of large effect sizes. For the participants in our study without a previous

history of BoNT, we generally observed effects that were smaller than our expectations. The data

we present here could be leveraged to design future studies that would allow more robust

statistical conclusions about such smaller effects. In general, despite this limitation, the smaller

effects we observed lead us to conclude that the passive torque differences we observed in the

paretic limb did not substantially limit passive ROM in these participants.

## CONCLUSIONS

To the best of our knowledge, the current study is the most thorough investigation of *in*

*vivo* passive elastic torques at the hand in the chronic hemiparetic stroke population.  Our

findings indicate that, after stroke, prolonged altered use and neural inputs to muscle do not

substantially increase or negatively impact the passive torques about either the wrist or fingers,

nor significantly limit passive extension at the fingers, unless an individual has received BoNT.

This suggests that clinically observed stiffness and loss of ROM is likely due to either neurally

driven muscle hypertonia or long-term detrimental increases in muscle stiffness following BoNT

injections. Additionally, this provides further evidence that in the absence of mechanical muscle

alterations, the loss of hand function post-stroke is primarily due to weakness from voluntary

activation deficits[6] and impaired control of the muscles of the hand[11,56] following disruptions of

corticofugal motor pathways.[62,63] Future rehabilitation techniques should therefore focus on

motor deficits post stroke to achieve improved hand function rather than preventing passive

mechanical changes. Additionally, the potential adverse effects of BoNT that our data highlights

should be explored to determine if the positive effects of reduced muscle hypertonia and

spasticity outweigh potential negative side effects of increased muscle stiffness in order to

maximize recovery of individuals following a hemiparetic stroke.

## ACKNOWLEDGEMENTS

We especially want to thank Dr. Arno Stienen and Paul Krueger for their assistance with the

custom device design and modification, and Vikram Darbhe for his assistance in experimental

set-up and data collection

*FUNDING SOURCES*

Promotion of Doctoral Studies Level II Scholarship from the Foundation for Physical Therapy,

American Heart Association Pre-Doctoral Fellowship: 16PRE30970010, National Institutes of

Health (NIH) T32EB009406 to J.P.A.D., and NIH Grant R01HD084009 to J.P.A.D. and W.M.M

*COMPETING INTERESTS*

Drs. Binder-Markey, Murray & Dewald report no disclosures, competing interests, or conflicts of

interest.

427
428

**REFERENCES**

1. Baker SN, Zaaimi B, Fisher KM, Edgley SA, Soteropoulos DS. Pathways mediating
functional recovery. *Prog Brain Res.* 2015;218:389-412.
2. Zaaimi B, Edgley SA, Soteropoulos DS, Baker SN. Changes in descending motor pathway
connectivity after corticospinal tract lesion in macaque monkey. *Brain.* 2012;135(Pt
7):2277-2289.
3. Ellis MD, Drogos J, Carmona C, Keller T, Dewald JP. Neck rotation modulates flexion
synergy torques, indicating an ipsilateral reticulospinal source for impairment in stroke.
*J Neurophysiol.* 2012;108(11):3096-3104.
4. McPherson JG, Chen A, Ellis MD, Yao J, Heckman CJ, Dewald JPA. Progressive
recruitment of contralesional cortico-reticulospinal pathways drives motor impairment
post stroke. *J Physiol.* 2018;596(7):1211-1225.
5. Karbasforoushan H, Cohen-Adad J, Dewald JPA. Brainstem and spinal cord MRI identifies
altered sensorimotor pathways post-stroke. *Nat Commun.* 2019;10(1):3524.
6. Hoffmann G, Conrad MO, Qiu D, Kamper DG. Contributions of voluntary activation
deficits to hand weakness after stroke. *Top Stroke Rehabil.* 2016;23(6):384-392.
7. Kamper DG, Fischer HC, Cruz EG, Rymer WZ. Weakness is the primary contributor to
finger impairment in chronic stroke. *Arch Phys Med Rehabil.* 2006;87(9):1262-1269.
8. Kamper DG, Harvey RL, Suresh S, Rymer WZ. Relative contributions of neural
mechanisms versus muscle mechanics in promoting finger extension deficits following
stroke. *Muscle Nerve.* 2003;28(3):309-318.
9. Dewald JP, Pope PS, Given JD, Buchanan TS, Rymer WZ. Abnormal muscle coactivation
patterns during isometric torque generation at the elbow and shoulder in hemiparetic
subjects. *Brain.* 1995;118 ( Pt 2):495-510.
10. Dewald JP, Sheshadri V, Dawson ML, Beer RF. Upper-limb discoordination in hemiparetic
stroke: implications for neurorehabilitation. *Top Stroke Rehabil.* 2001;8(1):1-12.
11. Miller LC, Dewald JP. Involuntary paretic wrist/finger flexion forces and EMG increase
with shoulder abduction load in individuals with chronic stroke. *Clin Neurophysiol.*
2012;123(6):1216-1225.
12. Sukal TM, Ellis MD, Dewald JP. Shoulder abduction-induced reductions in reaching work
area following hemiparetic stroke: neuroscientific implications. *Exp Brain Res.*
2007;183(2):215-223.
13. Brunnstrom S. *Movement therapy in hemiplegia: a neurophysiological approach.* 1st ed.
New York,: Medical Dept.; 1970.
14. Kamper DG, Rymer WZ. Quantitative features of the stretch response of extrinsic finger
muscles in hemiparetic stroke. *Muscle Nerve.* 2000;23(6):954-961.
15. McPherson JG, Ellis MD, Heckman CJ, Dewald JP. Evidence for increased activation of
persistent inward currents in individuals with chronic hemiparetic stroke. *J*
*Neurophysiol.* 2008;100(6):3236-3243.
16. McPherson JG, Stienen AH, Drogos JM, Dewald JP. Modification of Spastic Stretch
Reflexes at the Elbow by Flexion Synergy Expression in Individuals With Chronic
Hemiparetic Stroke. *Arch Phys Med Rehabil.* 2017.

17.    Bhadane MY, Gao F, Francisco GE, Zhou P, Li S. Correlation of Resting Elbow Angle with
472           Spasticity in Chronic Stroke Survivors. *Front Neurol.* 2015;6:183.
473    18.    O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke.
474           *Brain.* 1996;119 ( Pt 5):1737-1749.
475    19.    Lee JM, Gracies JM, Park SB, Lee KH, Lee JY, Shin JH. Botulinum Toxin Injections and
476           Electrical Stimulation for Spastic Paresis Improve Active Hand Function Following Stroke.
477           *Toxins (Basel).* 2018;10(11).
478    20.    Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper
479           limb spasticity after stroke or traumatic brain injury: a systematic review with meta-
480           analysis and trial sequential analysis. *Eur J Phys Rehabil Med.* 2017;53(2):256-267.
481    21.    Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary:
482           Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult
483           spasticity, and headache: Report of the Guideline Development Subcommittee of the
484           American Academy of Neurology. *Neurology.* 2016;86(19):1818-1826.
485    22.    Minamoto VB, Suzuki KP, Bremner SN, Lieber RL, Ward SR. Dramatic changes in muscle
486           contractile and structural properties after 2 botulinum toxin injections. *Muscle Nerve.*
487           2015;52(4):649-657.
488    23.    Ward SR, Minamoto VB, Suzuki KP, Hulst JB, Bremner SN, Lieber RL. Recovery of rat
489           muscle size but not function more than 1 year after a single botulinum toxin injection.
490           *Muscle Nerve.* 2017.
491    24.    Ates F, Yucesoy CA. Effects of botulinum toxin type A on non-injected bi-articular muscle
492           include a narrower length range of force exertion and increased passive force. *Muscle*
493           *Nerve.* 2014;49(6):866-878.
494    25.    Yucesoy CA, Ateş F. BTX-A has notable effects contradicting some treatment aims in the
495           rat triceps surae compartment, which are not confined to the muscles injected. *J*
496           *Biomech.* 2018;66:78-85.
497    26.    Thacker BE, Tomiya A, Hulst JB, et al. Passive mechanical properties and related proteins
498           change with botulinum neurotoxin A injection of normal skeletal muscle. *J Orthop Res.*
499           2012;30(3):497-502.
500    27.    Kaya CS, Yilmaz EO, Akdeniz-Dogan ZD, Yucesoy CA. Long-Term Effects With Potential
501           Clinical Importance of Botulinum Toxin Type-A on Mechanics of Muscles Exposed. *Front*
502           *Bioeng Biotechnol.* 2020;8:738.
503    28.    Pingel J, Wienecke J, Lorentzen J, Nielsen JB. Botulinum toxin injection causes hyper-
504           reflexia and increased muscle stiffness of the triceps surae muscle in the rat. *J*
505           *Neurophysiol.* 2016;116(6):2615-2623.
506    29.    Mathevon L, Michel F, Decavel P, Fernandez B, Parratte B, Calmels P. Muscle structure
507           and stiffness assessment after botulinum toxin type A injection. A systematic review.
508           *Ann Phys Rehabil Med.* 2015;58(6):343-350.
509    30.    Gao F, Grant TH, Roth EJ, Zhang LQ. Changes in passive mechanical properties of the
510           gastrocnemius muscle at the muscle fascicle and joint levels in stroke survivors. *Arch*
511           *Phys Med Rehabil.* 2009;90(5):819-826.
512    31.    Kwah LK, Herbert RD, Harvey LA, et al. Passive mechanical properties of gastrocnemius
513           muscles of people with ankle contracture after stroke. *Arch Phys Med Rehabil.*
514           2012;93(7):1185-1190.

32. Nelson CM, Murray WM, Dewald JPA. Motor Impairment-Related Alterations in Biceps
and Triceps Brachii Fascicle Lengths in Chronic Hemiparetic Stroke. *Neurorehabil Neural*
*Repair.* 2018;32(9):799-809.
33. Given JD, Dewald JP, Rymer WZ. Joint dependent passive stiffness in paretic and
contralateral limbs of spastic patients with hemiparetic stroke. *J Neurol Neurosurg*
*Psychiatry.* 1995;59(3):271-279.
34. Mirbagheri MM, Alibiglou L, Thajchayapong M, Rymer WZ. Muscle and reflex changes
with varying joint angle in hemiparetic stroke. *J Neuroeng Rehabil.* 2008;5:6.
35. Eby S, Zhao H, Song P, et al. Quantitative Evaluation of Passive Muscle Stiffness in
Chronic Stroke. *Am J Phys Med Rehabil.* 2016;95(12):899-910.
36. de Gooijer-van de Groep KL, de Vlugt E, van der Krogt HJ, et al. Estimation of tissue
stiffness, reflex activity, optimal muscle length and slack length in stroke patients using
an electromyography driven antagonistic wrist model. *Clin Biomech (Bristol, Avon).*
2016;35:93-101.
37. Sinkjaer T, Magnussen I. Passive, intrinsic and reflex-mediated stiffness in the ankle
extensors of hemiparetic patients. *Brain.* 1994;117 ( Pt 2):355-363.
38. Freire B, Dias CP, Goulart NB, et al. Achilles tendon morphology, plantar flexors torque
and passive ankle stiffness in spastic hemiparetic stroke survivors. *Clin Biomech (Bristol,*
*Avon).* 2017;41:72-76.
39. Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during
repeated passive movements in unilateral brain-injured patients. *Arch Phys Med*
*Rehabil.* 2000;81(3):269-278.
40. Opheim A, Danielsson A, Alt Murphy M, Persson HC, Sunnerhagen KS. Upper-limb
spasticity during the first year after stroke: stroke arm longitudinal study at the
University of Gothenburg. *Am J Phys Med Rehabil.* 2014;93(10):884-896.
41. Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity.
*Neurology.* 2013;80(3 Suppl 2):S13-19.
42. Levy J, Molteni F, Cannaviello G, Lansaman T, Roche N, Bensmail D. Does botulinum
toxin treatment improve upper limb active function? *Ann Phys Rehabil Med.*
2019;62(4):234-240.
43. Hara T, Momosaki R, Niimi M, Yamada N, Hara H, Abo M. Botulinum Toxin Therapy
Combined with Rehabilitation for Stroke: A Systematic Review of Effect on Motor
Function. *Toxins (Basel).* 2019;11(12).
44. Lawrence ES, Coshall C, Dundas R, et al. Estimates of the prevalence of acute stroke
impairments and disability in a multiethnic population. *Stroke.* 2001;32(6):1279-1284.
45. Broeks JG, Lankhorst GJ, Rumping K, Prevo AJ. The long-term outcome of arm function
after stroke: results of a follow-up study. *Disabil Rehabil.* 1999;21(8):357-364.
46. Parker VM, Wade DT, Langton Hewer R. Loss of arm function after stroke:
measurement, frequency, and recovery. *Int Rehabil Med.* 1986;8(2):69-73.
47. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. Recovery of upper extremity
function in stroke patients: the Copenhagen Stroke Study. *Arch Phys Med Rehabil.*
1994;75(4):394-398.
48. Gowland C, Stratford P, Ward M, et al. Measuring Physical Impairment and Disability
with the Chedoke-Mcmaster Stroke Assessment. *Stroke.* 1993;24(1):58-63.

49. Knutson JS, Kilgore KL, Mansour JM, Crago PE. Intrinsic and extrinsic contributions to the
passive moment at the metacarpophalangeal joint. *J Biomech.* 2000;33(12):1675-1681.

50. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1:
tests for correlation and regression analyses. *Behav Res Methods.* 2009;41(4):1149-
1160.

51. Stienen A, Moulton TS, Miller LC, Dewald JPA. Wrist and Finger Torque Sensor for the
Quantification of Upper Limb Motor Impairments Following Brain Injury. Paper
presented at: 2011 IEEE International Conference on Rehabilitation Robotics2011; Zurich ,
Switzerland.

52. Fraigne JJ, Torontali ZA, Snow MB, Peever JH. REM Sleep at its Core - Circuits,
Neurotransmitters, and Pathophysiology. *Front Neurol.* 2015;6:123.

53. Krenzer M, Anaclet C, Vetrivelan R, et al. Brainstem and spinal cord circuitry regulating
REM sleep and muscle atonia. *PLoS One.* 2011;6(10):e24998.

54. Hodes R, Dement WC. Depression of Electrically Induced Reflexes ("H-Reflexes") in Man
during Low Voltage Eeg "Sleep". *Electroencephalogr Clin Neurophysiol.* 1964;17:617-
629.

55. Magezi DA. Linear mixed-effects models for within-participant psychology experiments:
an introductory tutorial and free, graphical user interface (LMMgui). *Front Psychol.*
2015;6:2.

56. Lan Y, Yao J, Dewald JPA. The Impact of Shoulder Abduction Loading on Volitional Hand
Opening and Grasping in Chronic Hemiparetic Stroke. *Neurorehabil Neural Repair.*
2017;31(6):521-529.

57. Li S, Chen YT, Francisco GE, Zhou P, Rymer WZ. A Unifying Pathophysiological Account
for Post-stroke Spasticity and Disordered Motor Control. *Front Neurol.* 2019;10:468.

58. McPherson LM, Dewald JPA. Differences between flexion and extension synergy-driven
coupling at the elbow, wrist, and fingers of individuals with chronic hemiparetic stroke.
*Clin Neurophysiol.* 2019;130(4):454-468.

59. Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration,
and clinical ways of influencing them. *Toxicon.* 2015;107(Pt A):64-67.

60. Liu F, Tang W, Chen D, et al. Expression of TGF-beta1 and CTGF Is Associated with
Fibrosis of Denervated Sternocleidomastoid Muscles in Mice. *Tohoku J Exp Med.*
2016;238(1):49-56.

61. Faturi FM, Franco RC, Gigo-Benato D, et al. Intermittent stretching induces fibrosis in
denervated rat muscle. *Muscle Nerve.* 2016;53(1):118-126.

62. Kuypers HG. The Descending Pathways to the Spinal Cord, Their Anatomy and Function.
*Prog Brain Res.* 1964;11:178-202.

63. Lawrence DG, Kuypers HG. The functional organization of the motor system in the
monkey. I. The effects of bilateral pyramidal lesions. *Brain.* 1968;91(1):1-14.

Figure 1: Representative plots, from three separate individuals (A, B, & C), of EMG and torque

traces over 90 seconds within one of the initial stretches accommodating the participant to the

device and reducing muscle hypertonia. Displayed are raw rectified unfiltered data (blue lines),

rectified and filtered EMG (red lines), processed 1 second binned data (black lines), with EMG

threshold cutoff for active muscle (magenta lines). Though the participant was "relaxed" at the

beginning of each stretch there is significant EMG activity initially with subsequent EMG and

torque reduction within each. Example A demonstrates Flexor Digitorium Superficialis (FDS) and

Flexor Carpi Ulnaris (FCU) EMG initially firing at a low levels with activity decreasing and a

corresponding decrease in wrist torque that continues throughout the trial. Example B

demonstrates EMG activity reducing across all muscles with a corresponding decrease in finger

and wrist torque that continues throughout the trial. Example C demonstrates low levels of FDS

and high levels of FCU EMG hyperactivity initially with hyperactivity stopping within 15 seconds

and a corresponding decrease in wrist extension torque that continues throughout the trial.

Figure 2: Average metacarpophalangeal (MCP) torques measured in the paretic (red) and non-

paretic (blue) limbs over MCP joint range of motion for the (a) no-BoNT mildly, moderately, and

severely impaired and BoNT-injected groups. Data are shown for 3 of the 9 wrist postures tested,

including locked in 60 (left), 0 (middle), and -60 degrees flexion (right). Negative angles and

torques indicate extension, positive indicates flexion. (b) Average interlimb difference in MCP

torques (paretic torque minus non-paretic torque) for the same locked wrist postures in (a), for

each group (shaded grey bars). * denotes significant difference (p<0.005) in torques measured

between paretic and non-paretic limbs within the group. ** denotes significant difference

(p<0.005) from all other groups. Only the BoNT-injected torque differences were significantly

different between limbs and greater than the other groups. Error bars indicate one standard error

of measurement.

Figure 3: Average wrist torques measured in the paretic (red) and non-paretic (blue) limb over the

wrist's range of motion for the (a) no-BoNT mildly, moderately, and severely impaired and BoNT-

injected groups. Metacarpophalangeal (MCP) posture was locked in -60 (left), 0 (middle), and 75

degrees flexion (right). Negative angles and torques indicate extension and positive flexion. (b)

Average interlimb difference in wrist torques (paretic torques minus non-paretic torques) for each

group (shaded grey bars), at each locked MCP posture. * denotes significant difference ($p<0.005$)

in torques measured between paretic and non-paretic limbs within the group. ** denotes significant

difference ($p<0.005$) from all other groups. Only the BoNT-injected torque differences were

significantly different between limbs and greater than the other groups. Error bars indicate one

standard error of measurement.

Figure 4: Limits of the metacarpophalangeal (MCP) passive range of motion (ROM) in extension

throughout the custom device's nine available wrist postures for the no-BoNT (a) mildly, (b)

moderately, and (c) severely impaired and (d) BoNT-injected groups groups. All, but one BoNT-

injected subject (limited to -15 degrees), could be positioned in all 9 wrist postures, limits of ROM

for MCP presented are the average for the paretic (red) and non-paretic (blue) hands. MCP

extension of the paretic hand in the BoNT-injected and moderate groups were significantly less

than the non-paretic hand (*denotes $p <0.005$ between paretic v non-paretic hands). ** denotes

significant difference ($p<0.005$) from all other groups. Deficits in passive extension increased with

wrist extension.  No significant loss of passive MCP extension was observed in the severe or mild

groups. Error bars indicate one standard error of measurement.

647
648 **Table 1: Table of Inclusion/Exclusion Criteria for Participants**

| **Subject Inclusion Criteria** |
| --- |
| Stroke occurred at least one year prior to participation in the study |
| Paralysis confined to one side of the body |
| Ability to give informed consent |
| BoNT Group Only: History of BoNT injection in the paretic forearm |
| **Subject Exclusion Criteria** |
| Multiple Strokes |
| Stroke occurred in the cerebellum or brainstem |
| Impairment or injury in the unimpaired limb |
| Severe atrophy of the impaired limb |
| Severe concurrent medical problems |
| No-BoNT Groups: History of BoNT injection in the paretic forearm |

649
650
651

**Table 2: Subject Demographics.**
(CMHS – Chedoke McMaster Stroke Assessment Hand Score, MAS – Modified Ashworth Scale)

| Impairment Level | Sex | Age in years (SD) | Time Since Stroke in years (SD) | Age at time of stroke in years (SD) | Paretic Side | CMHS | MAS | Time Since Last BoNT Injection in years (SD) |
|---|---|---|---|---|---|---|---|---|
| BoNT-Injected Severe (n=7) | 6-M, 1-F | 56.7 (8.3) | 10.7 (5.3) | 46.0 (5.1) | 4-L,3-R | 2.85 (0.38) | 2.71 (0.48) | 4.5 (2.8) |
| No-BoNT Severe (n=9) | 6-M, 3-F | 60.28 (10.40) | 17.1 (7.91) | 43.2 (13.6) | 5-L, 4-R | 2.44 (0.73) | 2.17 (0.87) | n/a |
| Moderate (n=9) | 5-M, 4-F | 64.3 (7.95) | 13.2 (7.96) | 51.1 (12.5) | 6-L, 3-R | 4.22 (0.44) | 1.78 (0.94) | n/a |
| Mild (n=9) | 5-M, 4-F | 56.93 (12.18) | 8.41 (3.71) | 48.5 (9.8) | 1-L, 8-R | 6.44 (0.53) | 0.28 (0.57) | n/a |

Figure 1

Examples of muscle hyperactivity reduction during static stretching prior to data collection

Figure 2

**Total Finger Torque Data**

a)

MCP Joint Torque (N/cm)

Mild · Moderate · Severe · BoNT*,**

MCP Joint Angle (deg)

b)

Torque Difference (N/cm)

■Mild ■Moderate ■Severe ■BoNT * **

Figure 3

a)

Total Wrist Torque Data

Wrist Joint Torque (N/cm)

Wrist Joint Angle (deg)

b)

Torque Difference (N/cm)

■ Mild ■ Moderate ■ Severe ■ BoNT * **

Figure 4

Extension End MCP Range-of-Motion Throughout Wrist Postures

End Range MCP Joint Angle (deg)